Cartesian Therapeutics Inc. (RNAC)
RNAC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/0001453687-26-000064-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RNAC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001453687 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.8M |
| Net income | -$130.3M |
| Operating income | -$143.4M |
| Net margin | -4658.6% |
| Operating margin | -5127.1% |
| Revenue growth | -92.8% |
| Cash | $125.1M |
| Total assets | $296.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 66.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $123.0M cash; operating cash flow -$22.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 30,503,005 (2026-10-31); 26,003,606 a year earlier; 155,204,182 three years earlier. 3y figure adjusted for split (1-for-30 overall). | Cover page 2026-10-31 |
| Reverse splits, 3 years | 1; latest 1-for-30 on 2024-04-05 | Source 2024-04-05 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $206K, sold $259K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$11.5M | -$27.7M | $123.0M | $50.2M | $1.0M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $0 | $15.8M | -$21.1M | $147.6M | $52.9M | $1.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $78K | -$39.2M | -$22.1M | $118.6M | No debt tags | $1.8M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $947K | -$92.6M | -$17.7M | $125.1M | $0 | $2.8M | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | $452K | -$35.9M | -$15.6M | $143.4M | No debt tags | $1.1M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $298K | $15.9M | -$17.5M | $160.3M | No debt tags | $1.0M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $1.1M | -$17.7M | -$23.1M | $180.4M | No debt tags | $34.2M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | -$759K | -$10.3M | -$7.0M | $212.6M | No debt tags | $38.9M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2025-01-10 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEF 14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 877 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.7% |
| 1 month | -3.3% |
| 3 months | -27.2% |
| Year to date | -11.9% |
| 1 year | -12.2% |
| From 52-week high | -40.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NATR | Nature's Sunshine Products Inc. | $10.56 | +1.93% | $183.0M |
| SLGL | Sol-Gel Technologies Ltd. | $54.96 | -0.29% | $179.9M |
| WHWK | Whitehawk Therapeutics Inc. | $3.01 | -1.63% | $177.6M |
| TRDA | Entrada Therapeutics Inc. | $5.00 | -1.77% | $195.8M |
| NGEN | NervGen Pharma Corp. | $1.82 | -3.19% | $195.9M |
| KROS | Keros Therapeutics Inc. | $10.03 | -2.62% | $196.8M |
| KRRO | Korro Bio Inc. | $12.71 | -6.61% | $174.5M |
| IFRX | InflaRx N.V. | $1.18 | +0.85% | $173.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier